RecruitingNCT07608003

Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:

Application of MRI-Based Artificial Intelligence Models for Preoperative Molecular Subtyping and Prognostic Assessment of Midline Gliomas: A Multicenter Prospective Clinical Study

Sponsor

Xiangya Hospital of Central South University

Enrollment

500 participants

Start Date

May 10, 2026

Study Type

OBSERVATIONAL

Conditions

Gliomas Glioma Glioblastoma Multiforme Gliomas Harboring IDH1 and/or IDH2 Mutations Glioma of Brainstem Glioma, Diffuse Midline, H3K27M-mutant Glioma : Oligodendroglioma or Astrocytoma

Summary

A vision-language model using preoperative MRI and clinical variables has been developed to simultaneously predict three key molecular markers in midline gliomas: H3K27M, IDH, and 1p/19q. This prospective multicenter study will validate the model's accuracy in preoperative molecular subtyping and its value in prognostic assessment and clinical decision-making across multiple neurosurgical centers.

Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with glioma : oligodendroglioma or astrocytoma, glioma glioblastoma multiforme, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.